AfterRaise/Companies/EMED Technologies' Subsidiary

EMED Technologies' Subsidiary

EMED Technologies' Subsidiary is a developer of drug delivery and innovative infusion therapy devices. From its funding announcement.

$8M UndisclosedRaised 8 months agoEl Dorado Hills, USABiotech & PharmaUSA

In their own words

What EMED Technologies' Subsidiary says it is doing

Work here? Claim your company profile

Public signal Described in the funding announcement as "developer of drug delivery and innovative infusion therapy devices". Source

Why now

Where EMED Technologies' Subsidiary is today

EMED Technologies' Subsidiary announced a funding round of $8M on 25 February 2026.

Latest round
Undisclosed
Amount
$8M
Announced
25 February 2026
Headquarters
El Dorado Hills, USA
Sector
Biotech & Pharma
Growth stage
Growth
Investors
Not stated
Also participating
Not stated
Relevant leadership
Not stated

Momentum AfterRaise intelligence

AfterRaise Score

27
Established
0 funding signals in the last 90 days
Funding recency
9/40
announced within the last year
Round scale
8/25
round size relative to the market
Funding stage
10/20
Undisclosed
Funding cadence
0/15
one funding event tracked this year
Arriving with the signals layer
  • Hiring momentum Open roles and hiring pace
  • Market expansion New offices and new countries
  • Leadership Executive appointments
  • Product activity Launches and releases

Since the raise

What has happened since

  • 25 February 2026
    $8M raised
    Investors not stated in the announcement.

Public signal The timeline currently holds funding events, because those are the signals AfterRaise observes today. Hiring, leadership, expansion and product events join it with the signals layer.

What may happen next

What this raise could create

AfterRaise intelligenceNot a statement of fact

What may happen next

  • Operational scale
  • Market consolidation

Opportunities this could create

  • Clinical operations
  • Regulatory affairs
  • CMC and manufacturing
  • Quality systems
  • Medical affairs

Based on the Biotech & Pharma sector and a Growth round. Not a statement of fact.

Early momentum1 connected signal
  • 25 February 2026$8M round announced

High momentum means several meaningful company changes have occurred in a short period. Signals here are funding events and the priorities the company stated; hiring, leadership and expansion detection join with the signals layer.

Open to

What EMED Technologies' Subsidiary is open to

Not yet specified

EMED Technologies' Subsidiary has not told AfterRaise which approaches it welcomes. Until it does, we do not assume. Offers to help are held and shown to the company, and the company decides whether to open a conversation.

Work here? Set your preferences

Opportunities

Ways to work with EMED Technologies' Subsidiary

No open opportunities listed

Jobs, projects, partnerships, advisory and supplier needs appear here once the company has claimed its page and published them, and any role we read from its own job board appears automatically.

Work here? Open the first one

Helpful contributors

People who have contributed here

Nobody yet

When someone offers help and the company says it was useful, they appear here. Reputation on AfterRaise is built from contributions the company confirmed, not from follower counts.

Do you work at EMED Technologies' Subsidiary?

Claim your company profile.

This page was created from publicly available information. A verified representative corrects the record, says what the company is building next and chooses which conversations it welcomes.

What we do not have yet: your website, what the round is for, in your words, the roles and projects you have open and who leads the team. Claiming the page is how you fill those in.

Someone else requesting access does not give them ownership. Every representative is verified by a person before access is granted.

Maintaining your own company profile is free. A founder, CEO or authorised senior colleague can represent the company.

Also moving

Other Biotech & Pharma companies

See the sector